Bernie Sanders restarted the debate about single-payer health care by proposing “Medicare for all.” Bloomberg columnist Leonid Bershidsky pointed out that in Europe, his idea would hardly be radical. But columnist Megan McArdle finds the Sanders plan implausible in the U.S.
After just a few days into my visit to the U.S., no fewer than 10 people have told me this country will never adopt a European-style health care system. It’s incomprehensible to me. I live in Germany and, like 85 percent of all German residents, I’m covered by what’s known as statutory health insurance. It’s financed by mandatory contributions of 14.6 percent of income, shared 50/50 between employer and employee. The earner of the average German annual wage of $43,300 pays $263 per month, and any children he or she has – plus a spouse or partner who doesn’t work – are covered by this amount.
In the U.S., the average Obamacare premium is $408 per person.
Never miss a local story.
In general, per-capita health care spending is almost twice as high in the U.S. as it is in Germany, but Germans receive better service with better results. They enjoy shorter waiting times for surgery and specialist appointments, as well as better health outcomes.
For the smaller amount of money we pay, we get full coverage of our medical needs. We don’t worry about deductibles. The copayments we are sometimes expected to make for medicines and some special kinds of hospital care are far smaller than our grocery bills, and we don’t have to deal with any paperwork – we just hand our insurance card to the doctor and everything is taken care of. Pregnancies, chronic diseases, dental care – they’re all covered under statutory insurance. Medical debt? Never heard of it.
The remaining 15 percent of Germans are covered by private insurance, either because they’re self-employed or because they want an even higher level of service, shorter waiting times and coverage beyond medical necessity. For many corporate employees, including myself, personal contributions to statutory or private plans are covered by employers.
What’s not to like?
I’ve long opposed a comprehensive national health care system for America because the profligate, practically unmanaged, wildly uneven U.S. health care system is subsidizing innovation for everyone else, especially in drugs. Innovative products have two cost components: development and production. Someone has to pay that development cost, and if Europe bargains hard to get prices down to something like a cost-plus-modest-profit basis, another country has to pick up the tab. That country is us, because the drab task of turning likely targets into drugs that can be dispensed at commercial scale still largely falls to pharmaceutical companies. If Europe wants to keep its cheap systems yet continue to enjoy lifesaving advances, they ought to be saying, “Oh, no, it’s dreadful here. You’d hate it, really” instead of sneering across the Atlantic.
This is a cold moral calculus. But the number of people who will suffer and die from things we can’t now treat, but might, is much larger than the number of people who die in America from lack of insurance, which recent research suggests may be surprisingly close to zero.
The answer for “why don’t we” boils down to a few parts: First, we cannot get to European pricing levels; second, Americans don’t trust the government with a complete takeover of the health care system; and third, American politics is inhospitable to this sort of radical change.
A remarkable fallacy of the American health care system is that we have a huge cost-growth problem. We don’t. We did in the 1970s and 1980s, which seems strongly related to our last foray into government health insurance, the creation of Medicare. What we have is a very expensive medical plan and labor costs. Our providers are used to billing richly for their services and enjoying higher incomes than their counterparts in Europe.
Cutting the incomes of such a large group of workers, closing unprofitable hospitals, etc., is incredibly difficult. No European system has managed the kind of cuts that would be needed to get us to their pricing levels; what they did was keep costs from growing in the first place. We haven’t even managed modest changes such as keeping down the cost of Medicare reimbursements to doctors. As soon as the cost restraints began to bite, Congress rushed through a “temporary” fix, a ritual repeated annually until it became permanent.
We’re stuck with what we did 30 years ago, not what we should have done.
But why can’t we at least start controlling costs now? That goes to American politics, which is extremely decentralized compared with most European systems. Our party discipline is simply not strong enough to survive the heart-wrenching ads about nursing reimbursement cuts and emergency room closures, or the angry phone calls that rain down on lawmakers who dare to touch such powerful lobbies. It took a historic financial crisis to deliver huge congressional majorities, plus a fair amount of self-delusion on the part of Democrats, to get something like Obamacare passed.
Obamacare, where the insurance has proven much more expensive, and much less generous, than people expected, has certainly not increased their appetite for more government in this sector.
Post-Obamacare, we basically have the German system. Only we have what it looks like in America, badly deformed by our decentralized politics and crippled by our reluctance to tax the middle class.
There’s something to the argument that the U.S. system is inefficient only for Americans but great for the rest of the world. The pharmaceutical industry is highly globalized, and many important new drugs, even those marketed by European companies, are developed in the U.S. On the other hand, Viagra, for example, originated in Britain, even though Pfizer is a U.S. company. Pharmaceutical research takes place throughout the world, much of it in countries with lower development costs than in the U.S. The U.S. market is much bigger than the European one, but research and development expenditures in Europe and the U.S. are comparable. And the research wouldn’t stop if the U.S. moved to a comprehensive health care system: The same pharmaceutical companies operate profitably throughout the world, including Europe, and they would cheerfully keep doing so.
Germany is a highly decentralized country that consists of 16 federal states. It doesn’t have a single-payer health insurance system as such: There are 132 payers – so-called sickness funds – that collect people’s contributions. These funds are all members of an association; there is also an association that unites doctors who work with statutory insurance. These groups form a national committee to negotiate care standards, but they also negotiate prices and specific local issues on the state level. Pharmacies and drug manufacturers also take part in these negotiations.
This system results in lower drug prices than in the U.S. because most pharmaceutical companies want their products to be part of the statutory insurance system. Those that don’t want to can serve the remaining 15 percent of the population, if they can agree with private insurers.
The corporatist system of negotiations, of course, also drives down the incomes of medical professionals. A general practitioner in Germany makes an average of $52,000 a year, or 20 percent more than the national average. A U.S. general practitioner makes almost $142,000, or 250 percent of the national average. Reducing that disparity is a matter of competition and negotiation; besides, German doctors aren’t burdened with student debt (higher education is free).
You mentioned handing health care over to the government. Where is the government in the German scheme? Well, the parliament does regulate the system, particularly when fears arise that costs might get out of hand and the existing contribution level may not be enough. For the most part, however, it keeps out of dealings among quasi-public players such as the sickness funds, public and private hospitals (there are approximately equal numbers of these in Germany), and fully private players such as doctors, pharma companies and pharmacies.
Doesn’t this bargaining system – with the possibility of opting out in favor of a fully private arrangement – look quintessentially American? In the end, going from a dysfunctional system to a more promising one is a matter of determination. Obamacare is an example of insufficient determination: People got less than what they bargained for, at a higher price.
Obamacare was not America’s first time at the health-care-pricing rodeo. Saying that it’s a matter of determination is true but not helpful. Legislators are not determined enough to take on the provider lobby, because every time they do, they lose. There’s a reason medical-device manufacturers got the worst deal out of Obamacare, while insurers did middling-badly and providers did well. This is in roughly direct proportion to the number of voters each industry can move out to the polls when their income is cut.
We have a messy, fractious democracy that offers interest groups almost unlimited veto points against legislation they don’t like. These forces make our government extremely bad at controlling costs, which shows up not just in our health-care and education systems, but also in the price of building our infrastructure or providing various social services.